FDA-process and commercialization on track. New study results confirm the potential. Year-End Report (May-January 2018/2019)

SEK thousands                         Q4 18/19    Q4 17/18 May-April 18/19 May-April 17/18 Net sales                                               1,715           1,433                 3,005                    2,723 Operating profit (loss)                        -8,569          -4,132              -21,718                -17,956 Loss for the period                              -8,631          -4,176              -21,556                -18,010 Earnings per share, after dilution        -0.47            -0.24                  -1.18                     -1.01

2019-11-20T00:39:16+00:00 June 14th, 2019 08:00|Press Release|

FDA-process och kommersialisering enligt plan. Nya studiedata bekräftar potentialen. Bokslutskommuniké maj-april 2018/2019

kSEK                                         kv 4 18/19 kv 4 17/18 maj-apr 18/19        maj-apr 17/18 Nettoomsättning                              1 715         1 433          3 005          2 723 Rörelseresultat                                  -8 569        -4 132        -21 718      -17 956 Periodens resultat                             -8 631        -4 176        -21 556      -18 010 Resultat per aktie ef utspäd             -0,47          -0,24          -1,18           -1,01

2019-11-20T00:39:13+00:00 June 14th, 2019 08:00|Press Release|